Analytical Data
-
Gene name
CYP19A1
- Application
-
Alternative Names
CYPXIX;Cytochrome P-450AROM;Cytochrome P450 19A11 Publication;Estrogen synthase
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11511
-
Expression Region
1-503aa
-
Molecular Weight
62.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP19A1, also known as aromatase, is a crucial enzyme responsible for the conversion of androgens to estrogens, playing a pivotal role in estrogen biosynthesis. This protein is encoded by the CYP19A1 gene and is predominantly expressed in ovarian tissues, adipose tissue, and the brain. Dysfunctional aromatase activity has been implicated in various pathological conditions, including hormone-dependent cancers such as breast cancer and prostate cancer, as well as other disorders like osteoporosis and metabolic syndrome. Research into CYP19A1 recombinant proteins has gained significant momentum, as these proteins can be utilized to study enzymatic mechanisms, develop inhibitors, and understand estrogen's broader biological effects. Moreover, the production of CYP19A1 recombinants provides insights into post-translational modifications and enzyme kinetics essential for drug development. Furthermore, given the increasing interest in targeted therapies against estrogen-related diseases, the characterization of CYP19A1 recombinant proteins is particularly relevant for devising new strategies in cancer treatment and management. Overall, this research domain holds promise for advancing our understanding of estrogen metabolism and its implications in health and disease.
